Since there are no VGLUT inhibitors with appropriate specificity or drug-likeness, this study is to verify the role of VGLUT1 and VGLUT2 as a therapeutical target in brain ischemia, and thus to intensify research on innovative compound of clinical relevancy. The gene discussed is SLC17A6; the disease is brain ischemia.